Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 5.9% - Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) rose 5.9% on Wednesday . The company traded as high as $20.12 and last traded at $20.16. Approximately 59,154 shares were traded during trading, a decline of 78% from the average daily volume of 270,336 shares. The stock had previously closed at $19.04.

Wall Street Analyst Weigh In

DNTH has been the subject of a number of research analyst reports. Robert W. Baird decreased their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Finally, William Blair initiated coverage on Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating for the company. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Trading Up 0.2%

The stock has a market capitalization of $656.06 million, a P/E ratio of -7.08 and a beta of 1.38. The company has a 50-day moving average price of $18.61 and a 200 day moving average price of $20.24.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. As a group, research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNTH. Charles Schwab Investment Management Inc. grew its stake in Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after buying an additional 1,092 shares during the last quarter. Intech Investment Management LLC purchased a new position in Dianthus Therapeutics during the 4th quarter worth $201,000. American Century Companies Inc. grew its stake in Dianthus Therapeutics by 3.8% during the 4th quarter. American Century Companies Inc. now owns 43,996 shares of the company's stock worth $959,000 after buying an additional 1,629 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Dianthus Therapeutics during the 4th quarter worth $33,000. Finally, JPMorgan Chase & Co. grew its stake in Dianthus Therapeutics by 14.0% during the 4th quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company's stock worth $264,000 after buying an additional 1,490 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.